Is CAR-T Cell Therapy Available for Acute Myeloid Leukaemia?

Acute myeloid leukaemia (AML) is one of the fastest-moving, hardest-to-treat blood cancers - and one of the few major leukaemias where CAR-T cell therapy hasn't yet delivered the breakthrough seen elsewhere. Given how transformative CAR-T has been for certain lymphomas and B-cell leukaemias, it's a fair question patients and families keep asking: can the same approach be used against AML?

The honest, evidence-based answer in 2026 is: not yet, but not for lack of trying. Understanding exactly where the science stands - and what's already working in the meantime - makes it much easier to have an informed conversation with an oncologist, and to know what treatment path is realistically available.

Choosing where to pursue that treatment is its own challenge, especially for patients outside the countries where the newest therapies were first approved. This is a gap platforms like MediGence exist to close - by connecting patients with specialists who can translate the research below into an actual, personalised plan, rather than leaving them to interpret it alone.

Why AML Has Resisted CAR-T Where Other Blood Cancers Haven't

CAR-T therapy works by re-engineering a patient's own T-cells to recognise and destroy cancer cells carrying a specific surface marker. It has succeeded in B-cell lymphomas and leukaemias largely because the target antigen - commonly CD19 - is expressed almost exclusively on cancerous cells, and patients can tolerate the loss of healthy B-cells as a side effect.

AML doesn't offer that same margin for error. The surface markers found on leukaemic myeloid cells are, almost without exception, also present on healthy blood-forming stem cells. Turning engineered T-cells loose on those markers risks wiping out the bone marrow's ability to make blood altogether - a toxicity that has capped how aggressively AML-directed CAR-T can be dosed in trials so far. The disease's immunosuppressive tumour microenvironment and its wide biological variability among patients compound the problem, often blunting the survival and function of infused CAR-T cells.

So Where Does CAR-T for AML Actually Stand Right Now?

There is currently no CAR-T product approved by the FDA, EMA, or any major regulator specifically for AML. Every patient who receives CAR-T for AML today does so inside a clinical trial, at a specialised centre, and only after meeting criteria around antigen expression, prior treatment lines, and overall fitness.

That said, the pace of research has picked up meaningfully. A 2025 review of AML-directed CAR-T trials identified twenty-five separate studies, covering close to 300 patients treated between 2014 and early 2025 - most of them targeting three antigens: CD33, CD123, and CLL-1.

CAR-T Targets Currently Under Investigation for AML

Target Antigen	Rationale	Typical Trial Phase	Key Challenge Observed
CD33	Widely expressed on AML blasts	Phase I/II	Overlaps with normal myeloid cells, causing marrow suppression
CD123	Highly expressed on leukaemic stem cells	Phase I/II	On-target, off-tumour toxicity to normal progenitors
CLL-1 (CLEC12A)	More restricted to leukaemic cells than CD33/CD123	Phase I/II	Early data promising, still limited patient numbers
CD7	Explored in mixed myeloid/lymphoid leukaemias	Early phase	Risk of T-cell fratricide requiring gene editing
NKG2D-ligand based	Broader stress-antigen targeting approach	Early phase	Variable persistence of CAR-T cells
CD38	Also explored in multiple myeloma	Early phase	Antigen shared with other normal tissues

Because these trials are scattered across a small number of specialised centres worldwide, and eligibility varies considerably from one protocol to the next, finding out whether a given patient's leukaemia even matches an open trial is often the hardest part of the process - this is exactly the kind of case-matching MediGence's medical teams help patients work through before any travel decision is made.

What the Clinical Data Actually Show

Response rates across these trials have been described as heterogeneous, and remissions achieved with CAR-T alone tend to be short-lived unless followed up with an allogeneic stem cell transplant. On safety, cytokine release syndrome and neurotoxicity - the two most talked-about CAR-T complications - have generally been low-grade and manageable in AML studies. The bigger limiting factor has been prolonged, severe myelosuppression, which sometimes requires a transplant just to restore normal blood cell production. Disease progression, rather than treatment toxicity, remains the leading reason patients don't see lasting benefit.

Several engineering strategies are now being tested specifically to work around these limitations:

Dual-targeting CARs, which only activate when two antigens are present together, sparing more healthy tissue
Inhibitory, "logic-gated" CAR designs, engineered to switch off in the presence of a marker found on healthy cells
Gene-edited, "off-the-shelf" allogeneic CAR-T cells, using TCR knockout and HLA/CD52 editing to reduce rejection risk and speed up manufacturing
Sequential CAR-T followed by stem cell transplant, used deliberately to consolidate remission rather than as a standalone cure

The Treatments That Are Already Approved and Working

While CAR-T remains experimental, AML care overall has moved forward substantially in the last two years - mostly on the back of oral, mutation-specific drugs that are already changing how the disease is managed day to day.

Currently approved AML therapies (2026)

Therapy Class	Example Drugs	Approved For	What It Targets
Menin inhibitors	Revumenib, ziftomenib	Relapsed/refractory AML with KMT2A rearrangement or NPM1 mutation	Blocks the meninâ€“KMT2A interaction driving leukaemic gene expression
FLT3 inhibitors	Midostaurin, gilteritinib, quizartinib	Newly diagnosed or relapsed FLT3-mutated AML	FLT3 tyrosine kinase signalling
IDH1/IDH2 inhibitors	Ivosidenib, enasidenib, olutasidenib	Relapsed/refractory AML with IDH1 or IDH2 mutation	Mutant IDH enzyme activity
BCL-2 inhibitors	Venetoclax (plus azacitidine/HMA)	Newly diagnosed AML, especially in patients unfit for intensive chemotherapy	Apoptosis pathway in leukaemic cells
Hedgehog pathway inhibitor	Glasdegib	Newly diagnosed AML with low-dose cytarabine	Smoothened (SMO) receptor signalling
Antibody-drug conjugate	Gemtuzumab ozogamicin	CD33-positive AML	Delivers chemotherapy directly to CD33+ cells
Allogeneic stem cell transplant	-	Eligible patients in remission, especially high-risk cytogenetics	Replaces marrow with a donor immune system

Several of these, particularly the menin inhibitors, are recent enough - approved within the last one to two years - that access outside the country of first approval is still uneven. That gap in availability is precisely why so many patients start looking beyond their home healthcare system in the first place, and why comparing where a specific drug, transplant programme, or trial is actually accessible matters as much as comparing hospitals. MediGence's network of 500+ accredited hospitals across more than 24 countries, along with transparent, real-time cost comparisons, is designed to make that comparison possible before a patient commits to travelling anywhere.

Three Questions Worth Asking Before Deciding Where to Be Treated

For patients weighing treatment abroad - including many in Russia, where some of the newer targeted therapies and trial slots remain hard to access - three questions tend to matter more than any others:

Does my AML carry a druggable mutation? Genomic testing for FLT3, IDH1/IDH2, NPM1, and KMT2A status should be performed early, as it directly determines eligibility for the most recently approved therapies.
Am I a candidate for a clinical trial, including CAR-T? Eligibility depends on prior treatment lines, the antigen profile of the leukaemic cells, and overall fitness - best assessed by a centre actively running AML cellular therapy trials, not guessed at from general information.
Is a stem cell transplant part of the plan? Many of the deepest, most durable remissions in AML - including those achieved after CAR-T - still rely on transplant for consolidation.

Getting clear answers to these three questions early is usually what separates a well-informed treatment decision from a rushed one. It's also where a second opinion from a specialist haemato-oncologist - arranged through MediGence's teleconsultation platform before any travel is booked - tends to be most valuable, since it turns abstract trial and drug data into a plan specific to one patient's mutation profile and prior treatment history.

A Realistic Takeaway

CAR-T cell therapy for AML is a genuinely active and promising area of research, but it's not yet something a patient can simply request. Access remains limited to clinical trials at a small number of centres, and results so far are encouraging without being definitive. The more immediate, accessible progress in AML care has come from oral, mutation-targeted drugs - menin, FLT3, and IDH inhibitors among them - several of which have only reached approval in the past one to two years.

For anyone navigating this landscape from outside the country where these therapies are approved, the practical path forward usually starts the same way: confirm the mutation profile, get an independent specialist opinion, and find out - concretely - which hospitals, drugs, and trials are actually within reach. MediGence exists to make that first step easier, connecting patients with the right specialists, comparing hospitals and costs across its global network, and coordinating everything from the first consultation through travel, treatment, and follow-up care.